168 related articles for article (PubMed ID: 34324021)
1. Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.
Strapatsas J; Barbulescu EC; Lauseker M; Kaivers J; Hildebrandt B; Nachtkamp K; Strupp C; Rudelius M; Haas R; Germing U
Ann Hematol; 2021 Oct; 100(10):2575-2584. PubMed ID: 34324021
[TBL] [Abstract][Full Text] [Related]
2. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
5. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
Martín M; de Paz R; Jiménez-Yuste V; Fernández Bello I; García Arias Salgado E; Alvarez MT; Butta NV
Thromb Haemost; 2013 May; 109(5):909-19. PubMed ID: 23407717
[TBL] [Abstract][Full Text] [Related]
6. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Al Ameri A; Jabbour E; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Shan J; Pierce S; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):237-41. PubMed ID: 21575929
[TBL] [Abstract][Full Text] [Related]
7. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients.
Houwerzijl EJ; Blom NR; van der Want JJ; Louwes H; Esselink MT; Smit JW; Vellenga E; de Wolf JT
Blood; 2005 May; 105(9):3472-9. PubMed ID: 15542580
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
9. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1).
Jonasova A; Cermak J; Vondrakova J; Siskova M; Hochova I; Kadlckova E; Cerna O; Sykora M; Vozobulova V; Seifertova N; Michalova K; Zemanova Z; Brezinova J; Belohlavkova P; Kostecka A; Neuwirtova R
Leuk Res; 2012 Dec; 36(12):e222-4. PubMed ID: 22954608
[No Abstract] [Full Text] [Related]
11. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.
Mo A; Wood E; Shortt J; Hu E; McQuilten Z
Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616
[TBL] [Abstract][Full Text] [Related]
12. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
Psaila B; Bussel JB; Frelinger AL; Babula B; Linden MD; Li Y; Barnard MR; Tate C; Feldman EJ; Michelson AD
J Thromb Haemost; 2011 Nov; 9(11):2302-10. PubMed ID: 21920014
[TBL] [Abstract][Full Text] [Related]
13. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
14. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.
Sandes AF; Yamamoto M; Matarraz S; Chauffaille Mde L; Quijano S; López A; Oguro T; Kimura EY; Orfao A
Haematologica; 2012 Jun; 97(6):895-902. PubMed ID: 22271903
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; Ricco A; Palumbo GA; Impera S; Di Renzo N; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Candoni A; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Bova I; D'Errigo MG; Zini G; Latagliata R
J Clin Oncol; 2023 Oct; 41(28):4486-4496. PubMed ID: 37294914
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
17. Deficient in vitro megakaryocytopoiesis and decreased in vivo platelet turnover in children and young adults with chronic thrombocytopenia.
Parker RI; Siegel RS; Ratajczak MZ; Gewirtz AM
J Pediatr Hematol Oncol; 1998; 20(3):196-201. PubMed ID: 9628429
[TBL] [Abstract][Full Text] [Related]
18. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
Garcia-Manero G; Scott BL; Cogle CR; Boyd TE; Kambhampati S; Hetzer J; Dong Q; Kumar K; Ukrainskyj SM; Beach CL; Skikne BS
Leuk Res; 2018 Sep; 72():79-85. PubMed ID: 30114559
[TBL] [Abstract][Full Text] [Related]
19. [A preliminary study of prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes].
Chen YD; Xu ZF; Cui R; Wang JY; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Zhang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):532-5. PubMed ID: 22967412
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.
Elzaeem DI; Sharkawi EAE; Zaki EM; Ghobrial AG; El-Fatah ASA; El-Hamed WMA
Ann Hematol; 2021 Jul; 100(7):1701-1709. PubMed ID: 33982136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
